Alkem Laboratories has tied up with Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG) for OA indication. Under this agreement, Alkem will get the exclusive marketing rights for Stempeucel in India for osteoarthritis with stempeutics manufacturing and supplying the product to Alkem. The product is expected to be available in Indian market by 2020 after undergoing the Phase 3 Clinical trial in India, which is expected to commence in 2018. Earlier Stempeutics has successfully completed a Phase 2 clinical trial in India and the outcomes have been published in the peer-reviewed indexed journal Arthritis Research & Therapy, UK.
Current OA treatments are more symptomatic in nature whereas Stempeucel drug has a potential to address the root cause of the disease. In Phase III trial – Stempeucel used ultrasound guidance and new MRI techniques called T2 to map and assess the quality of articular cartilage and also to assess the quantitative analyses of articular cartilage.
Leave a Reply